Estimation of the burden of shielding among a cross section of patients attending rheumatology clinics with SLE – data from the BSR audit of Systemic Lupus ErythematosusCitation formats
Standard
Estimation of the burden of shielding among a cross section of patients attending rheumatology clinics with SLE – data from the BSR audit of Systemic Lupus Erythematosus. / Rutter, Megan; Lanyon, Peter; Sandhu, Raj; Batten, Rebecca; Garner, Rebecca ; Little, Jayne; Narayan, Nehal; Sharp, Charlotte; Bruce, Ian; Erb, Nicola; Griffiths, Bridget; Guest, Hannah; Macphie, Elizabeth; Packham, Jon; Hiley, Chris; Obrenovic, Karen; Rivett, Ali; Gordon, Caroline; Pearce, Fiona A .
In: Rheumatology (Print), Vol. 60, No. 3, 02.03.2021, p. 1474 – 1479 .Research output: Contribution to journal › Article › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Estimation of the burden of shielding among a cross section of patients attending rheumatology clinics with SLE – data from the BSR audit of Systemic Lupus Erythematosus
AU - Rutter, Megan
AU - Lanyon, Peter
AU - Sandhu, Raj
AU - Batten, Rebecca
AU - Garner, Rebecca
AU - Little, Jayne
AU - Narayan, Nehal
AU - Sharp, Charlotte
AU - Bruce, Ian
AU - Erb, Nicola
AU - Griffiths, Bridget
AU - Guest, Hannah
AU - Macphie, Elizabeth
AU - Packham, Jon
AU - Hiley, Chris
AU - Obrenovic, Karen
AU - Rivett, Ali
AU - Gordon, Caroline
AU - Pearce, Fiona A
N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
PY - 2021/3/2
Y1 - 2021/3/2
N2 - OBJECTIVES: We aimed to estimate what proportion of people with SLE attending UK rheumatology clinics would be categorized as being at high risk from coronavirus disease 2019 (COVID-19) and therefore asked to shield, and explore what implications this has for rheumatology clinical practice.METHODS: We used data from the British Society for Rheumatology multicentre audit of SLE, which included a large, representative cross-sectional sample of patients attending UK Rheumatology clinics with SLE. We calculated who would receive shielding advice using the British Society for Rheumatology's risk stratification guidance and accompanying scoring grid, and assessed whether ethnicity and history of nephritis were over-represented in the shielding group.RESULTS: The audit included 1003 patients from 51 centres across all 4 nations of the UK. Overall 344 (34.3%) patients had a shielding score ≥3 and would have been advised to shield. People with previous or current LN were 2.6 (1.9-3.4) times more likely to be in the shielding group than people with no previous LN (P < 0.001). Ethnicity was not evenly distributed between the groups (chi-squared P < 0.001). Compared with White people, people of Black ethnicity were 1.9 (1.3-2.8) and Asian 1.9 (1.3-2.7) times more likely to be in the shielding group. Increased risk persisted after controlling for LN.CONCLUSION: Our study demonstrates the large number of people with SLE who are likely to be shielding. Implications for clinical practice include considering communication across language and cultural differences, and ways to conduct renal assessment including urinalysis, during telephone and video consultations for patients who are shielding.
AB - OBJECTIVES: We aimed to estimate what proportion of people with SLE attending UK rheumatology clinics would be categorized as being at high risk from coronavirus disease 2019 (COVID-19) and therefore asked to shield, and explore what implications this has for rheumatology clinical practice.METHODS: We used data from the British Society for Rheumatology multicentre audit of SLE, which included a large, representative cross-sectional sample of patients attending UK Rheumatology clinics with SLE. We calculated who would receive shielding advice using the British Society for Rheumatology's risk stratification guidance and accompanying scoring grid, and assessed whether ethnicity and history of nephritis were over-represented in the shielding group.RESULTS: The audit included 1003 patients from 51 centres across all 4 nations of the UK. Overall 344 (34.3%) patients had a shielding score ≥3 and would have been advised to shield. People with previous or current LN were 2.6 (1.9-3.4) times more likely to be in the shielding group than people with no previous LN (P < 0.001). Ethnicity was not evenly distributed between the groups (chi-squared P < 0.001). Compared with White people, people of Black ethnicity were 1.9 (1.3-2.8) and Asian 1.9 (1.3-2.7) times more likely to be in the shielding group. Increased risk persisted after controlling for LN.CONCLUSION: Our study demonstrates the large number of people with SLE who are likely to be shielding. Implications for clinical practice include considering communication across language and cultural differences, and ways to conduct renal assessment including urinalysis, during telephone and video consultations for patients who are shielding.
KW - Adult
KW - COVID-19/prevention & control
KW - Cross-Sectional Studies
KW - Female
KW - Humans
KW - Lupus Erythematosus, Systemic/therapy
KW - Lupus Nephritis/therapy
KW - Male
KW - Medical Audit
KW - Middle Aged
KW - Patient Acceptance of Health Care/statistics & numerical data
KW - Practice Patterns, Physicians'/statistics & numerical data
KW - Quarantine/statistics & numerical data
KW - Regression Analysis
KW - Rheumatology/statistics & numerical data
KW - SARS-CoV-2
KW - Telemedicine/statistics & numerical data
KW - United Kingdom/epidemiology
U2 - 10.1093/rheumatology/keaa620
DO - 10.1093/rheumatology/keaa620
M3 - Article
C2 - 33677595
VL - 60
SP - 1474
EP - 1479
JO - Rheumatology (Print)
JF - Rheumatology (Print)
SN - 1462-0324
IS - 3
ER -